Following Ultragenyx’s announcement that its Phase 3 Aspire trial of GTX-102 did not meet its primary or key secondary endpoints, the Angelman Syndrome Foundation (ASF) and FAST hosted a community webinar with Ultragenyx.
The webinar provided an opportunity for the Angelman community to hear from Ultragenyx about the trial results and ask questions.
